Citation Impact
Citing Papers
Neutrophil-Derived Proteins: Selling Cytokines by the Pound
1999
Removing T-cell epitopes with computational protein design
2014 StandoutNobel
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
2006 StandoutScience
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
2016
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Cancer statistics, 2022
2022 Standout
Inadequate erythropoietin response to anemia: definition and clinical relevance
1994
Cancer statistics, 2023
2023 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Cancer statistics, 2017
2017 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2019
2019 Standout
Cancer statistics, 2018
2018 Standout
Cancer Statistics, 2021
2021 Standout
Neurotrophic factors in Alzheimer’s and Parkinson’s disease brain
2000
Leukotrienes and Other Products of the 5-Lipoxygenase Pathway
1990
Aspirin-Triggered 15-Epi-Lipoxin A4 and Stable Analogs of Lipoxin A4 are Potent Inhibitors of Acute Inflammation
1999
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
2008 Standout
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
2017 StandoutNobel
New treatment for acute myelogenous leukemia
2014
Panning of multiple subsets of leukocytes on antibody-decorated poly(ethylene) glycol-coated glass slides
2006
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
The past and future of CD33 as therapeutic target in acute myeloid leukemia
2014
International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors
2003
Cancer drug resistance: an evolving paradigm
2013 Standout
Altered Tumor-Cell Glycosylation Promotes Metastasis
2014
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
2015
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
2008 Standout
Cancer stem cells revisited
2017 Standout
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
2014
Nonresolving Inflammation
2010 Standout
Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells
2003 Standout
Neutrophils in the activation and regulation of innate and adaptive immunity
2011 Standout
The development of allergic inflammation
2008 StandoutNature
Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
2014
The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo
2006
Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution
2005
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Inflammation and cancer: back to Virchow?
2001 Standout
Lipoxin biosynthesis and its impact in inflammatory and vascular events
1994
Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: Conversion to novel 15-oxo and dihydro products
1993
Origin and physiological roles of inflammation
2008 StandoutNature
Platelet Activation During Allergic Inflammation
2007
Mammalian lipoxygenases: molecular structures and functions
1992
Topoisomerase I inhibitors: camptothecins and beyond
2006 Standout
Mitoxantrone
1996
Lipoxin Biosynthesis by Trout Macrophages Involves the Formation of Epoxide Intermediates
1994
Anemia of Chronic Disease
2005 Standout
Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma.Identification of a subset at high risk of treatment failure
1994
Cancer drugs and the heart: importance and management
2012
Mitoxantrone, Etoposide, and Cytarabine With or Without Valspodar in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome: A Phase III Trial (E2995)
2004
E-Prostanoid-3 Receptors Mediate the Proinflammatory Actions of Prostaglandin E2 in Acute Cutaneous Inflammation
2004 StandoutNobel
Patterned Hydrogels for Controlled Platelet Adhesion from Whole Blood and Plasma
2010 StandoutNobel
Tumour stem cells and drug resistance
2005 Standout
Acute Myeloid Leukemia
2015 Standout
Cyclooxygenases: Structural, Cellular, and Molecular Biology
2000 Standout
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
2002
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Increased Acute Inflammation, Leukotriene B4-Induced Chemotaxis, and Signaling in Mice Deficient for G Protein-Coupled Receptor Kinase 6
2003 StandoutNobel
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
2013
Functions of Ceramide in Coordinating Cellular Responses to Stress
1996 StandoutScience
Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome
2000
Toward the potential cure of leukemias in the next decade
2018
Dioxygen Activation at Mononuclear Nonheme Iron Active Sites: Enzymes, Models, and Intermediates
2004 Standout
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
2011
Antibody therapy for acute myeloid leukaemia
2013
Cancer statistics, 2016
2016 Standout
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Cancer statistics, 2015
2015 Standout
Altered inflammatory responses in leukotriene-deficient mice.
1994
Chemistry of Biologically Important Synthetic Organoselenium Compounds
2001 Standout
A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone
2010 Standout
Resolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases
2003
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
Implications of ATP-binding cassette transporters for brain pharmacotherapies
2007
Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways
2006
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Free Radicals in the Physiological Control of Cell Function
2002 Standout
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine
2012
Biology of Cachexia
1997
Treatments for chronic myeloid leukemia: a qualitative systematic review
2012
Works of Leif Stenke being referenced
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
2015
Leukotrienes and lipoxins—New potential performers in the regulation of human myelopoiesis
1994
Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
2009
Formation and proliferative effects of lipoxins in human bone marrow
1991
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
2011
Mitoxantrone, Etoposide and Cytarabine in the Treatment of Acute Nonlymphocytic Leukemia
1990
Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation
2011
Increase of serum interleukin‐2 and regression of myeloma after rhGM‐CSF treatment of drug induced bone marrow aplasia
1991
Leukotriene production by fresh human bone marrow cells: evidence of altered lipoxygenase activity in chronic myelocytic leukemia.
1987
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
2013
On the mechanism of transcellular lipoxin formation in human platelets and granulocytes
1991
Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia
1991
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy
2010
Stimulation of human myelopoiesis by leukotrienes B4 and C4: interactions with granulocyte-macrophage colony-stimulating factor
1993
Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
2013
Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.
2009
Aberrant expression of active leukotriene C4 synthase in CD16+ neutrophils from patients with chronic myeloid leukemia
2000
Expression of mRNA encoding neurotrophins and neurotrophin receptors in human granulocytes and bone marrow cells—enhanced neurotrophin-4 expression induced by LTB4
1998
Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
1993
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia
2003
P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein–Positive Acute Myeloid Leukemia
2000
Tumor necrosis factor-alpha and interferon-gamma in serum of multiple myeloma patients.
1990
Lipoxygenase products in myeloproliferative disorders: increased leukotriene C4 and decreased lipoxin formation in chronic myeloid leukemia.
1991